Therapeutic Antibodies in Medicine

Correction Critical Care Medicine

Real World Effectiveness of Benralizumab in Severe Eosinophilic Asthma (vol 159, pg 496, 2022)

[Anonymous]

CHEST (2023)

添加到收藏夹

Editorial Material Biochemistry & Molecular Biology

Pathogenesis of Alzheimer's Disease

Agueda A. Rostagno

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

添加到收藏夹

Article Medicine, General & Internal

Lecanemab in Early Alzheimer's Disease

Christopher H. van Dyck et al.

Summary: Lecanemab, a humanized monoclonal antibody, reduced amyloid markers and showed improvement in cognition and function in early Alzheimer's disease patients. However, it also resulted in adverse events. Longer trials are needed to determine its efficacy and safety in early Alzheimer's disease.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

Computational and artificial intelligence-based methods for antibody development

Jisun Kim et al.

Summary: Due to the high specificity and binding affinity, therapeutic antibodies are the largest class of biotherapeutics. However, the traditional antibody development process is cumbersome and has limitations. Recent advances in computational and AI technologies are helping to overcome these limitations and are integrated into development pipelines.

TRENDS IN PHARMACOLOGICAL SCIENCES (2023)

添加到收藏夹

Article Rheumatology

A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus

Kenneth C. Kalunian et al.

Summary: This study investigates the long-term safety and tolerability of anifrolumab 300 mg compared with placebo in patients with systemic lupus erythematosus (SLE). The results show that anifrolumab is well-tolerated and has a favorable benefit-risk profile in patients with moderate-to-severe SLE receiving standard therapy.

ARTHRITIS & RHEUMATOLOGY (2023)

添加到收藏夹

Letter Endocrinology & Metabolism

Teplizumab approval for type 1 diabetes in the USA

Carmella Evans-Molina et al.

LANCET DIABETES & ENDOCRINOLOGY (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

Retifanlimab: First Approval

Connie Kang

Summary: Milestones in the Development of Retifanlimab: Retifanlimab, developed by Incyte Corporation, is a PD-1 receptor-blocking antibody used for the treatment of solid tumors as monotherapy or in combination with other agents. It has recently received accelerated approval for metastatic or recurrent locally advanced Merkel cell carcinoma.

DRUGS (2023)

添加到收藏夹

Correction Clinical Neurology

Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis ( MycarinG): a randomised, double- blind, placebo- controlled, adaptive phase 3 study (vol 22, pg 383, 2023)

V Bril et al.

LANCET NEUROLOGY (2023)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Efficient evolution of human antibodies from general protein language models

Brian L. L. Hie et al.

Summary: Natural evolution explores vast sequence space for rare mutations, and learning from it can guide artificial evolution. A study found that general protein language models can efficiently evolve human antibodies by suggesting evolutionarily plausible mutations, even without target antigen, binding specificity, or protein structure information. Language-model-guided affinity maturation improved the binding affinities of clinically relevant antibodies up to sevenfold and unmatured antibodies up to 160-fold, with favorable thermostability and viral neutralization activity. The models also guided efficient evolution across diverse protein families and selection pressures.

NATURE BIOTECHNOLOGY (2023)

添加到收藏夹

Article Medicine, General & Internal

Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis

Jonathan I. Silverberg et al.

Summary: Two 52-week trials showed that treatment with lebrikizumab was effective in improving skin condition and reducing itch severity in patients with moderate-to-severe atopic dermatitis. The incidence of adverse events was generally mild to moderate and did not lead to trial discontinuation.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Article Medicine, General & Internal

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

M. R. Mirza et al.

Summary: Dostarlimab plus carboplatin-paclitaxel significantly improved progression-free survival in patients with endometrial cancer, particularly in the mismatch repair-deficient microsatellite instability-high population.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Article Oncology

Artificial intelligence in cancer immunotherapy: Applications in neoantigen recognition, antibody design and immunotherapy response prediction

Tong Li et al.

Summary: Cancer immunotherapy aims to control and eliminate tumors by reactivating the body's immune response. With advancements in AI and high-performance computing, AI is increasingly used in oncology research, particularly in immunotherapy, for tasks such as neoantigen recognition and antibody design. The progress in AI applications will lead to more accurate predictive models, better target identification, and improved treatments, ultimately advancing precision oncology.

SEMINARS IN CANCER BIOLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial

William J. Sandborn et al.

Summary: This study compared the safety and efficacy of two doses of Etrolizumab with placebo in patients with Crohn's disease. The results showed that during the maintenance phase, Etrolizumab significantly improved clinical remission and endoscopic improvement in patients with moderately to severely active Crohn's disease compared to placebo. However, there was no significant difference in the effects of Etrolizumab and placebo on clinical remission and endoscopic improvement during the induction phase.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

Tremelimumab: First Approval

Susan J. J. Keam

Summary: Tremelimumab, a CTLA-4 blocking antibody, has been approved for the treatment of unresectable hepatocellular carcinoma and metastatic non-small cell lung cancer in the USA. It has also received a positive opinion for the first-line treatment of advanced or unresectable HCC from the EU Committee for Medicinal Products for Human Use. The drug is currently under regulatory review in Japan and other countries worldwide.

DRUGS (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Mirvetuximab Soravtansine: First Approval

Young-A Heo

DRUGS (2023)

添加到收藏夹

Review Oncology

Elranatamab: a new promising BispAb in multiple myeloma treatment

Sebastian Grosicki et al.

Summary: Multiple myeloma is a B-cell malignancy caused by proliferating plasma cells in the bone marrow microenvironment. Despite improvement in treatment, it remains incurable and prone to relapse. Elranatamab is a promising new therapeutic option with potential for more potent anti-myeloma activity.

EXPERT REVIEW OF ANTICANCER THERAPY (2023)

添加到收藏夹

Meeting Abstract Immunology

A phase 2/3 study evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE disease)

Ahmet Ozen et al.

IMMUNOBIOLOGY (2023)

添加到收藏夹

Article Medicine, General & Internal

Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis

Geert D'Haens et al.

Summary: Mirikizumab was superior to placebo in inducing and maintaining clinical remission in patients with moderately to severely active ulcerative colitis. Adverse events such as nasopharyngitis and arthralgia were reported more frequently in the Mirikizumab group. Only a small number of patients treated with Mirikizumab had opportunistic infections or cancer.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Article Medicine, General & Internal

Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis

Jonathan I. Silverberg et al.

Summary: The study shows that lebrikizumab is effective in treating moderate-to-severe atopic dermatitis in both adolescents and adults, with significant improvements in skin lesions and reduction of itch symptoms during the 16-week induction period.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials

Paul Guedeney et al.

Summary: Treatment with alirocumab or evolocumab is associated with reduced risk of myocardial infarction, stroke, and coronary revascularization, with a favorable safety profile.

EUROPEAN HEART JOURNAL (2022)

添加到收藏夹

Article Oncology

Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers

Yulong Zheng et al.

Summary: This study evaluated the safety and anti-tumor activity of penpulimab in patients with advanced upper gastrointestinal (UGI) cancers. The results showed that penpulimab monotherapy demonstrated acceptable safety and encouraged anti-tumor activity in these patients, warranting further exploration in a larger cohort of patients.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

添加到收藏夹

Article Clinical Neurology

Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial

Uwe Reuter et al.

Summary: In this study comparing erenumab to topiramate for migraine prophylaxis, erenumab demonstrated a more favorable tolerability and efficacy profile, with fewer patients discontinuing medication due to adverse events and significantly more patients achieving a >= 50% reduction in monthly migraine days.

CEPHALALGIA (2022)

添加到收藏夹

Article Respiratory System

Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension

Mark Toshner et al.

Summary: The study examined the therapeutic effects of blocking the IL-6 signaling pathway in PAH patients, with inconsistent treatment outcomes.

EUROPEAN RESPIRATORY JOURNAL (2022)

添加到收藏夹

Article Allergy

Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis

Patrick Baum et al.

Summary: This study revealed that the IL-36 pathway plays a significant role in the pathogenesis of generalized pustular psoriasis. Treatment with spesolimab, an anti-IL-36 receptor antibody, resulted in rapid improvement of skin and pustular symptoms in patients with GPP. The treatment also modulated dysregulated molecular pathways associated with GPP and PPP, leading to improved clinical outcomes.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)

添加到收藏夹

Article Oncology

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial

Caicun Zhou et al.

Summary: The GEMSTONE-302 trial showed that sugemalimab plus chemotherapy significantly improved progression-free survival in previously untreated squamous and non-squamous metastatic NSCLC patients compared to placebo plus chemotherapy, regardless of PD-L1 expression. These findings have important implications for the first-line treatment of squamous and non-squamous metastatic NSCLC.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Medicine, Research & Experimental

BioPhi: A platform for antibody design, humanization, and humanness evaluation based on natural antibody repertoires and deep learning

David Prihoda et al.

Summary: Despite manual and laborious traditional humanization methods, automated methods are advancing. The BioPhi platform offers novel approaches for humanization and evaluation, providing more efficient design and discovery of therapeutic antibodies.

MABS (2022)

添加到收藏夹

Article Medicine, General & Internal

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

Hussein A. Tawbi et al.

Summary: LAG-3 and PD-1 are two distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination of relatlimab and nivolumab has been shown to be safe and effective in previously treated melanoma patients, and this study aimed to evaluate its safety and activity in previously untreated melanoma patients. The results demonstrated that the combination therapy provided a greater benefit in terms of progression-free survival compared to nivolumab alone, without any new safety signals.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Immunology

Pegylation Reduces the Uptake of Certolizumab Pegol by Dendritic Cells and Epitope Presentation to T-Cells

Marie de Bourayne et al.

Summary: By investigating the role of PEGylation in T-cell reactivity, it has been demonstrated that pegylation reduces antigen capture by dendritic cells, peptide presentation to T-cells, and T-cell priming.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Oncology

Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma

Yusheng Guo et al.

Summary: This study evaluated the efficacy and safety of transarterial chemoembolization (TACE) combined with camrelizumab in treating recurrent hepatocellular carcinoma (R-HCC). The results showed that TACE-camrelizumab had similar efficacy to TACE-alone in terms of objective response rate, disease control rate, progression-free survival, and survival rates. Neutrophil-to-lymphocyte ratio was significantly associated with progression-free survival. Adverse events related to camrelizumab were observed in a majority of patients, but none were severe.

BMC CANCER (2022)

添加到收藏夹

Article Oncology

Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial

Zi-Xian Wang et al.

Summary: This study found that toripalimab combined with paclitaxel and cisplatin can significantly improve progression-free survival and overall survival in patients with treatment-naive advanced esophageal squamous cell carcinoma, with manageable safety.

CANCER CELL (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Nivolumab Plus Relatlimab: First Approval

Julia Paik

Summary: Nivolumab plus relatlimab is a combination immunotherapy treatment being developed for multiple types of advanced cancers. The treatment targets immune checkpoints using monoclonal antibodies. In March 2022, it received its first approval in the USA for unresectable or metastatic melanoma.

DRUGS (2022)

添加到收藏夹

Article Medicine, General & Internal

Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction The PACMAN-AMI Randomized Clinical Trial

Lorenz Raber et al.

Summary: Among patients with acute myocardial infarction, the addition of biweekly subcutaneous alirocumab to high-intensity statin therapy resulted in significantly greater regression of coronary plaques in non-infarct-related arteries after 52 weeks. Further research is needed to understand whether alirocumab improves clinical outcomes in this population.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

添加到收藏夹

Review Neurosciences

Safety and Efficacy of Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials

Eleonora Lacorte et al.

Summary: This study reviewed registered trials investigating mAbs in AD and MCI due to AD, and analyzed safety and efficacy outcomes. The results suggest that the risk-benefit profile of mAbs remains unclear, highlighting the need for further research.

JOURNAL OF ALZHEIMERS DISEASE (2022)

添加到收藏夹

Article Oncology

Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study

Lin Shen et al.

Summary: Tislelizumab significantly improves overall survival in patients with advanced or metastatic ESCC, and has a tolerable safety profile. Patients with TAP >= 10% also demonstrate significant survival benefit with tislelizumab compared to chemotherapy.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Endocrinology & Metabolism

A systematic review and meta-analysis of efficacy and safety of Romosozumab in postmenopausal osteoporosis

S. Singh et al.

Summary: The study illustrates the significant effect of Romosozumab in reducing fractures and falls, as well as increasing bone mineral density in postmenopausal osteoporosis patients. The results suggest that Romosozumab treatment may be recommended for this patient population based on evidence of efficacy and safety.

OSTEOPOROSIS INTERNATIONAL (2022)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

Jason J. Luke et al.

Summary: The study demonstrates that Pembrolizumab as adjuvant therapy significantly prolongs recurrence-free survival in patients with stage II melanoma, with manageable safety profile.

LANCET (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety

Frank Kolbinger et al.

Summary: Psoriasis, psoriatic arthritis, and axial spondyloarthritis are systemic inflammatory diseases with varied symptoms and treatment responses. Secukinumab, a drug targeting IL-17A, has been used for over 6 years in the treatment of these diseases and has specific pharmacological properties.

PHARMACOLOGY & THERAPEUTICS (2022)

添加到收藏夹

Article Medicine, General & Internal

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

J. Cortes et al.

Summary: Among patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane, trastuzumab deruxtecan was associated with a lower risk of disease progression or death compared to trastuzumab emtansine. However, treatment with trastuzumab deruxtecan was associated with interstitial lung disease and pneumonitis.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants

Laura L. Hammitt et al.

Summary: A single injection of nirsevimab administered before the RSV season protected healthy late-preterm and term infants from medically attended RSV-associated lower respiratory tract infection.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Review Hematology

Monoclonal antibodies used for the management of hemataological disorders

Kanjaksha Ghosh et al.

Summary: Monoclonal antibodies are increasingly used in hematology practice, either alone or in combination with other therapies, to improve outcomes in various hematological conditions. These antibodies have a wide range of applications in malignant and benign hematological diseases, as well as in different phases of stem cell transplantation. Advancements in protein engineering are rapidly improving the function of antibodies.

EXPERT REVIEW OF HEMATOLOGY (2022)

添加到收藏夹

Review Geriatrics & Gerontology

Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer's Disease: A Focus on Aducanumab and Lecanemab

Mingchao Shi et al.

Summary: Alzheimer's disease is the most prevalent form of age-related dementia in the world, with limited treatment options available to provide only partial symptomatic relief. Disease-modifying therapies, targeting the systemic failure of cell-mediated Aβ clearance, are currently being studied in clinical trials.

FRONTIERS IN AGING NEUROSCIENCE (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Evinacumab for the treatment of homozygous familial hypercholesterolemia

Yanli Gao et al.

Summary: This review examines the pharmacological characteristics, clinical evidence, and safety of evinacumab, an ANGPTL3 inhibitor. Phase 3 clinical trials showed that evinacumab can significantly reduce LDL-C levels in patients with HoFH, making it a potential valuable treatment option.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2022)

添加到收藏夹

Article Hematology

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Meletios A. Dimopoulos et al.

Summary: Elotuzumab plus lenalidomide and dexamethasone did not significantly improve progression-free survival compared to lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients who are ineligible for HSCT. Further research is needed to improve frontline treatments.

LANCET HAEMATOLOGY (2022)

添加到收藏夹

Review Cell Biology

Role of Estrogens in Menstrual Migraine

Rossella E. Nappi et al.

Summary: Migraine is a significant neurological disorder with a major impact on healthcare and socioeconomic systems. Reproductive hormones, especially estrogens, play a crucial role in the pathophysiology of migraine, and prescribing exogenous estrogens may be an effective and safe treatment option for menstrual-related migraine.

CELLS (2022)

添加到收藏夹

Review Oncology

Sintilimab for the treatment of non-small cell lung cancer

Lin Zhang et al.

Summary: This study provides an overview of the clinical trials on Sintilimab for non-small cell lung cancer (NSCLC) conducted in China, showing its effectiveness and tolerability, but further research is needed.

BIOMARKER RESEARCH (2022)

添加到收藏夹

Article Economics

Modern Infectious Diseases: Macroeconomic Impacts and Policy Responses

David E. Bloom et al.

Summary: This article discusses the macroeconomic effects of epidemics and pandemics since the late twentieth century, covering the assessment of economic burden, policy trade-offs, and mitigation strategies. It examines the health and economic impacts of five infectious diseases and highlights the importance of early and targeted interventions.

JOURNAL OF ECONOMIC LITERATURE (2022)

添加到收藏夹

Review Health Care Sciences & Services

Economic Burden of COVID-19: A Systematic Review

Fayolah Richards et al.

Summary: This article reviews and synthesizes the evidence on the economic burden of COVID-19, including healthcare resource utilization and costs. The study found that patients with severe COVID-19 were associated with higher costs, mainly driven by ICU admission and in-hospital resource use such as mechanical ventilation. Productivity losses were the most frequently reported indirect costs. Older patients incurred higher costs compared to younger age groups. A Monte Carlo simulation estimated a total direct medical cost of $163.4 billion in the United States based on a 20% COVID-19 infection rate. Preventive measures such as non-pharmaceutical interventions only partially succeeded in reducing the economic costs of the pandemic. Implementing additional measures such as large-scale vaccination is crucial in reducing direct and indirect medical costs, productivity losses, and GDP losses.

CLINICOECONOMICS AND OUTCOMES RESEARCH (2022)

添加到收藏夹

Article Oncology

Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies

Kim Kramer et al.

Summary: The prognosis for metastatic and recurrent tumors of the central nervous system (CNS) remains dismal. This study explored the use of intraventricular radioimmunotherapy with anti-B7H3 antibody Omburtamab for targeting CNS malignancies. The results showed promising therapeutic benefits and favorable dosimetry and safety.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Michael J. Dickinson et al.

Summary: Glofitamab therapy is effective for DLBCL, but more than half of the patients experience grade 3 or 4 adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody

Ajai Chari et al.

Summary: Talquetamab treatment exhibited common adverse events like cytokine release syndrome, skin-related events, and dysgeusia, which were primarily low-grade; however, the drug induced substantial response among patients with heavily pretreated relapsed or refractory multiple myeloma.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Oncology

Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS)

Yutaka Yamamoto et al.

Summary: This study aimed to examine the efficacy of pertuzumab retreatment for HER2-positive locally advanced or metastatic breast cancer. The results showed that adding pertuzumab significantly improved progression-free survival in all patients and showed a trend towards better overall survival and duration of response.

CANCER SCIENCE (2022)

添加到收藏夹

Article Oncology

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)

Mariano Provencio et al.

Summary: Neoadjuvant chemotherapy plus nivolumab demonstrates effectiveness in resectable non-small cell lung cancer. Pretreatment ctDNA levels significantly correlate with survival outcomes and outperform radiologic assessments in predicting survival.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Efficacy and safety of cosibelimab, an anti–PD-L1 antibody, in patients with metastatic cutaneous squamous cell carcinoma.

Philip R. Clingan et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

Lihua E. Budde et al.

Summary: The study evaluated the safety and efficacy of fixed-duration mosunetuzumab in patients with relapsed or refractory follicular lymphoma. The results showed that mosunetuzumab has a favorable safety profile and induces high rates of complete remissions.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial

Andrea Sartore-Bianchi et al.

Summary: This study aimed to use blood-based testing of RAS/BRAF/EGFR mutation levels to guide anti-EGFR therapy in patients with colorectal cancer. The results showed that rechallenge therapy with panitumumab, guided by liquid biopsies, had favorable outcomes compared to standard treatments. This suggests that liquid biopsies can effectively and safely guide treatment decisions in patients with mCRC.

NATURE MEDICINE (2022)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Antibodies to combat viral infections: development strategies and progress

Giuseppe Pantaleo et al.

Summary: Monoclonal antibodies are attractive as potential therapeutics and prophylactics for viral infections due to their high specificity and ability to enhance immune responses. Advances in antibody engineering and structural biology have led to the development of monoclonal antibodies targeting various viruses, and have implications for vaccine design.

NATURE REVIEWS DRUG DISCOVERY (2022)

添加到收藏夹

Article Medicine, General & Internal

Teclistamab in Relapsed or Refractory Multiple Myeloma

Philippe Moreau et al.

Summary: Teclistamab demonstrated promising efficacy in patients with relapsed or refractory multiple myeloma, leading to high rates of deep and durable response. Common adverse events included cytokine release syndrome, cytopenias, and infections, with toxic effects mostly grade 1 or 2.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Trial of Prasinezumab in Early-Stage Parkinson's Disease

G. Pagano et al.

Summary: The study found that prasinezumab had no meaningful effect on global or imaging measures of Parkinson's disease progression and was associated with infusion reactions.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma

Stephen M. Ansell et al.

Summary: The study found that using A+AVD for the treatment of stage III or IV Hodgkin's lymphoma provides a survival advantage over ABVD.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer The ASTRUM-005 Randomized Clinical Trial

Ying Cheng et al.

Summary: This study evaluated the efficacy and adverse event profile of the PD-1 inhibitor serplulimab plus chemotherapy compared with placebo plus chemotherapy as first-line treatment in patients with extensive-stage SCLC. The results showed that serplulimab plus chemotherapy significantly improved overall survival and progression-free survival compared with chemotherapy alone, supporting its use as a first-line treatment for patients with previously untreated extensive-stage SCLC.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

添加到收藏夹

Review Clinical Neurology

Use of natalizumab in persons with multiple sclerosis: 2022 update

Sarah A. Morrow et al.

Summary: A group of neurologists from Canada convened in September 2021 to update the 2015 Canadian practice recommendations for the use of natalizumab in patients with multiple sclerosis (MS). The updated recommendations focus on long-term efficacy and safety data, patient selection based on JCV index criteria, risk management strategies for progressive leukoencephalopathy (PML), and options for switching to alternative disease-modifying therapies.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

添加到收藏夹

Review Immunology

Current landscape and future directions of bispecific antibodies in cancer immunotherapy

Jing Wei et al.

Summary: This review provides insights into the various structures of bispecific antibodies (BsAbs), their different mechanisms of action, and current clinical progress in cancer immunotherapy. Despite their potential, the application of BsAbs is hindered by challenges such as immunogenicity, tumor heterogeneity, low response rate, treatment resistance, and systemic adverse effects.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Development of therapeutic antibodies for the treatment of diseases

Zeng Wang et al.

Summary: The therapeutic antibody drug market is experiencing explosive growth, with various therapeutic antibodies being approved or under regulatory review. Innovations in research and development are continuously advancing, leading to significant progress in the fields of biology and medicine.

MOLECULAR BIOMEDICINE (2022)

添加到收藏夹

Article Critical Care Medicine

Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial

Jean Chastre et al.

Summary: This study assessed the effectiveness of the bivalent, bispecific monoclonal antibody MEDI3902 in preventing hospital-acquired pneumonia caused by Pseudomonas aeruginosa. The results showed that MEDI3902 did not reduce the incidence of pneumonia in Pseudomonas aeruginosa carriers.

CRITICAL CARE (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study

Maria Luisa Brandi et al.

Summary: This post hoc subgroup analysis demonstrates that burosumab has significant advantages in improving hypophosphatemia symptoms in adults with X-linked hypophosphatemia (XLH), including pain, stiffness, physical function, and fatigue. In various clinically relevant subgroups, burosumab shows superior efficacy compared to placebo.

CALCIFIED TISSUE INTERNATIONAL (2022)

添加到收藏夹

Review Immunology

Targeted Immunotherapy for Autoimmune Disease

Seung Min Jung et al.

Summary: Biological drugs and small molecule inhibitors have become the standard-of-care for treating autoimmune diseases, but there are still challenges in terms of therapeutic efficacy and safety profiles. Emerging therapies using advanced molecular engineering techniques aim to induce immune tolerance and overcome these challenges.

IMMUNE NETWORK (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Emerging new therapeutic antibody derivatives for cancer treatment

Shijie Jin et al.

Summary: This review article introduces the potential of monoclonal antibodies as targeted anticancer agents and their applications in cancer therapy. It also discusses various types of antibodies, clinical study advances, and the rationale and mechanisms of different antibody formats. Well-designed novel antibodies are paving the way for successful treatments of various cancers in the clinic.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)

添加到收藏夹

Article Clinical Neurology

A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis

Edward Fox et al.

Summary: The study demonstrated that Ublituximab is safe and effective in relapsing multiple sclerosis patients, leading to rapid depletion of B-cells and significant reductions in MRI activity and relapses.

MULTIPLE SCLEROSIS JOURNAL (2021)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis

Paul Guedeney et al.

Summary: This study compared the efficacy and safety of alirocumab and evolocumab in patients with dyslipidaemia or established atherosclerotic cardiovascular disease. The results showed that there were no significant differences in efficacy endpoints between the two drugs, except for a better reduction in all-cause death with alirocumab. However, alirocumab had a higher risk of injection site reactions compared to evolocumab.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Comparison of Long-term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naive Patients with Ulcerative Colitis

Yong Il Lee et al.

Summary: In this study, infliximab and adalimumab showed similar treatment efficacy and long-term outcomes in biologic-naive patients with moderate to severe UC. The analysis revealed that an elevated C-reactive protein level (>5 mg/L) was a significant predictive factor for poor outcomes in these patients.

GUT AND LIVER (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single-Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate

Anne J. Paccaly et al.

Summary: In this study, pharmacokinetics, pharmacodynamics, and PK/PD relationships of two different drugs for rheumatoid arthritis patients were evaluated. The onset of efficacy and safety profiles were similar for both drugs, despite differences in pharmacokinetics. This suggests that subcutaneous sarilumab and intravenous tocilizumab have comparable effects in reducing inflammation and maintaining white blood cell count in patients with inadequate responses to methotrexate.

JOURNAL OF CLINICAL PHARMACOLOGY (2021)

添加到收藏夹

Article Dermatology

Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)

A. Wollenberg et al.

Summary: Tralokinumab monotherapy was found to be superior to placebo at 16 weeks of treatment in two 52-week phase III trials, ECZTRA 1 and ECZTRA 2, and was well tolerated up to 52 weeks of treatment with sustained efficacy.

BRITISH JOURNAL OF DERMATOLOGY (2021)

添加到收藏夹

Article Hematology

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Michael U. Callaghan et al.

Summary: Long-term data from pooled studies show that prophylaxis with emicizumab maintains low bleed rates in persons with hemophilia A of all ages, with good tolerability and no new safety concerns.

BLOOD (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

REGN-EB3: First Approval

Anthony Markham

Summary: REGN-EB3, a combination of three fully-human monoclonal antibodies targeting Ebola virus glycoprotein, was recently approved by the US FDA based on the PALM study conducted during an Ebola outbreak in the Democratic Republic of Congo. This marks a significant milestone in the development of REGN-EB3 as a treatment for Zaire ebolavirus infection in adult and paediatric patients.

DRUGS (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases

Massimo Nicolo et al.

Summary: Faricimab, a promising bispecific drug targeting VEGF-A and the Ang-Tie pathway, has demonstrated clinical efficacy for w-AMD and DME. It is poised to become a new option in the anti-VEGF treatment market, with the Ang/Tie pathway potentially serving as an additional weapon for the treatment of w-AMD, DME, and RVO.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Casirivimab/Imdevimab: First Approval

Emma D. Deeks

Summary: Casirivimab/imdevimab is a combination drug approved for the treatment and prevention of COVID-19 in several countries, including the USA, India, Canada, Switzerland, Japan, and the UK, with emergency use authorizations or conditional approvals granted for its use.

DRUGS (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Regdanvimab: First Approval

Yahiya Y. Syed

Summary: Regdanvimab, a recombinant human monoclonal antibody targeting SARS-CoV-2, has received full approval in South Korea for treating COVID-19, particularly in elderly patients with underlying medical conditions and patients with mild to moderate symptoms.

DRUGS (2021)

添加到收藏夹

Review Pediatrics

Ranibizumab: A Review in Retinopathy of Prematurity

Arnold Lee et al.

Summary: Lucentis(R) is an effective anti-VEGF agent for retinopathy of prematurity, showing promising treatment success without systemic VEGF suppression observed in clinical trials.

PEDIATRIC DRUGS (2021)

添加到收藏夹

Editorial Material Hematology

Concizumab: a novel anti-TFPI therapeutic for hemophilia

Amy D. Shapiro

Summary: Concizumab is a novel subcutaneous prophylactic therapy for hemophilia that binds to the Kunitz-2 domain of TFPI, preventing it from blocking the FXa active site, thus achieving hemostasis. Clinical trials have shown that Concizumab has a favorable safety profile and significant reduction in bleeding rates, especially in inhibitor patients.

BLOOD ADVANCES (2021)

添加到收藏夹

Review Chemistry, Medicinal

Monoclonal Antibodies as Neurological Therapeutics

Panagiotis Gklinos et al.

Summary: Monoclonal antibodies play a crucial role in therapy and have revolutionized treatment in neurology. Ongoing research is exploring the potential of more monoclonal antibodies for treating neurological diseases, with a focus on understanding disease mechanisms for more precise targeted therapy.

PHARMACEUTICALS (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Naxitamab: First Approval

Anthony Markham

Summary: Naxitamab is a humanised anti-GD2 monoclonal antibody developed for the treatment of neuroblastoma and other GD2-positive cancers, which has recently received accelerated approval from the US FDA. This antibody, in combination with a cell-stimulating factor, demonstrates therapeutic effects in patients with partial response, minor response, or stable disease.

DRUGS (2021)

添加到收藏夹

Article Medicine, General & Internal

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Anil Gupta et al.

Summary: In this study, among nonhospitalized patients with symptomatic Covid-19, sotrovimab treatment significantly reduced the risk of disease progression leading to hospitalization or death compared to placebo. Patients receiving sotrovimab also had a lower rate of serious adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

John Kuruvilla et al.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Donanemab in Early Alzheimer's Disease

Mark A. Mintun et al.

Summary: In this study, donanemab showed improved composite scores for cognition and daily living activities compared to placebo in patients with early Alzheimer's disease at 76 weeks, although secondary outcomes varied. Longer and larger trials are needed to further explore the efficacy and safety of donanemab in Alzheimer's disease.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Cell Biology

Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals

Emily K. Sims et al.

Summary: A single 14-day course of teplizumab treatment in high-risk individuals showed lasting effects on delaying type 1 diabetes diagnosis and improving beta cell function. Changes in CD8(+) T cell subsets indicated that partially exhausted effector cells were associated with clinical response to immune therapy. This trial demonstrated improvements in metabolic responses and diabetes delay with immune therapy.

SCIENCE TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Article Cell Biology

Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer

Jiawen Yang et al.

Summary: This study demonstrates that cetuximab enhances the cytotoxic effect of RSL3 on KRAS mutant CRC cells by regulating the p38/Nrf2/HO-1 axis to promote ferroptosis. These findings suggest a potential strategy to overcome drug resistance in KRAS mutant colorectal cancer.

CELL DEATH & DISEASE (2021)

添加到收藏夹

Review Pediatrics

Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis

Hannah A. Blair

Summary: Subcutaneous secukinumab is an effective treatment option for children and adolescents with moderate to severe plaque psoriasis, providing fast and durable skin clearance, continuous improvement in health-related quality of life, and long-term maintained benefits.

PEDIATRIC DRUGS (2021)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease

Paul M. Ridker et al.

Summary: IL-6 is a pivotal cytokine in innate immunity with a proatherogenic role in cardiovascular disease. Research has explored mechanisms of IL-6 signaling, murine models, and human epidemiological data regarding its utility as a biomarker of vascular risk.

CIRCULATION RESEARCH (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Ansuvimab: First Approval

Arnold Lee

Summary: Ansuvimab, developed by Ridgeback Biotherapeutics, is a human monoclonal antibody approved in the USA for treating Zaire ebolavirus infection in both adult and paediatric patients. It blocks the entry of Ebola virus into host cells by binding to the virus glycoprotein.

DRUGS (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Margetuximab: First Approval

Anthony Markham

Summary: Margetuximab, a second-generation anti-HER2 monoclonal antibody, has been approved in the USA for the treatment of previously-treated metastatic HER2-positive breast cancer, based on its improved binding to activating Fc gamma receptor IIIA and reduced binding to inhibitory Fc gamma receptor IIB, aiming to enhance response rates.

DRUGS (2021)

添加到收藏夹

Article Oncology

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

Paolo F. Caimi et al.

Summary: Loncastuximab tesirine shows substantial antitumor activity and acceptable safety profile in patients with relapsed or refractory DLBCL, potentially offering a new therapeutic option for heavily pretreated individuals.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

Robert L. Coleman et al.

Summary: This study evaluated the efficacy and safety of tisotumab vedotin in women with recurrent or metastatic cervical cancer. The drug showed clinically meaningful and durable antitumour activity with a manageable and tolerable safety profile in this patient population. Tisotumab vedotin could represent a new treatment option for women with recurrent or metastatic cervical cancer.

LANCET ONCOLOGY (2021)

添加到收藏夹

Review Oncology

A comprehensive comparison between camelid nanobodies and single chain variable fragments

Yasaman Asaadi et al.

Summary: By comparing the structure and properties of camelid antibodies (VHHs) and single-chain variable fragments (scFvs), it can be determined which one is more suitable for their respective therapeutic, diagnostic, and research applications.

BIOMARKER RESEARCH (2021)

添加到收藏夹

Article Medicine, General & Internal

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

A. Bardia et al.

Summary: Patients with metastatic triple-negative breast cancer treated with Sacituzumab govitecan had significantly longer progression-free and overall survival compared to standard chemotherapy, but experienced more frequent myelosuppression and diarrhea as adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Sutimlimab in Cold Agglutinin Disease

Alexander Roeth et al.

Summary: In patients with cold agglutinin disease, treatment with sutimlimab rapidly halted hemolysis, increased hemoglobin levels, and reduced fatigue by selectively inhibiting activity in the classic complement pathway.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Bimekizumab versus Secukinumab in Plaque Psoriasis

Kristian Reich et al.

Summary: In patients with moderate-to-severe psoriasis, treatment with bimekizumab resulted in greater skin clearance than treatment with secukinumab over 16 and 48 weeks but was associated with oral candidiasis. Longer and larger trials are needed to determine comparative effects and risks of interleukin-17 inhibitors in psoriasis.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma

Andrew Menzies-Gow et al.

Summary: Tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin, effectively reduces asthma exacerbations in patients with severe, uncontrolled asthma, leading to improved lung function, asthma control, and quality of life.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Tumor microenvironment as a therapeutic target in cancer

Yi Xiao et al.

Summary: This article summarizes the current progress in targeting the tumor microenvironment in both drug development and clinical trials, emphasizing the challenges in intervening in the tumor microenvironment and discussing strategies to maximize therapeutic benefits. New technologies and approaches to better understand the tumor microenvironment are explored in this context.

PHARMACOLOGY & THERAPEUTICS (2021)

添加到收藏夹

Review Endocrinology & Metabolism

Burosumab for Pediatric X-Linked Hypophosphatemia

Erik A. Imel

Summary: X-Linked hypophosphatemia (XLH) is the most common genetic cause of rickets, and treatment with burosumab has shown significant improvements in both children and adults. However, many questions remain regarding its impact on various outcomes.

CURRENT OSTEOPOROSIS REPORTS (2021)

添加到收藏夹

Review Infectious Diseases

Socioeconomic Impact of RSV Hospitalization

Michal Young et al.

Summary: RSV disease is a significant global health burden among young children, particularly in developing countries. Risk factors for severe RSV disease include age and premature birth, which can lead to serious consequences and increased healthcare resource utilization.

INFECTIOUS DISEASES AND THERAPY (2021)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections

Hilal Ahmad Parray et al.

Summary: The route of administration plays a crucial role in the success of therapeutic agents, with inhalation being a promising strategy for treating respiratory diseases by providing higher concentrations of drugs in the respiratory airways and overcoming the limitations of systemic administration.

APPLIED MICROBIOLOGY AND BIOTECHNOLOGY (2021)

添加到收藏夹

Article Biochemical Research Methods

Humanization of antibodies using a machine learning approach on large-scale repertoire data

Claire Marks et al.

Summary: The study developed machine learning classifiers to distinguish between human and non-human antibody sequences, and used them to create a computational humanization tool, Hu-mAb, which suggests mutations to reduce immunogenicity of antibody therapeutics. The tool's results show a negative relationship with experimental immunogenicity and can effectively replace trial-and-error humanization experiments in a shorter amount of time.

BIOINFORMATICS (2021)

添加到收藏夹

Article Oncology

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Keunchil Park et al.

Summary: Amivantamab demonstrates robust and durable responses with tolerable safety in patients with EGFR Exon20ins mutations, even after progression on platinum-based chemotherapy.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Philippe Moreau et al.

Summary: The study showed that the addition of isatuximab to carfilzomib-dexamethasone significantly improves progression-free survival and depth of response in patients with relapsed multiple myeloma, representing a new standard of care for this patient population.

LANCET (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

Hai-Qiang Mai et al.

Summary: The study is a double-blind phase 3 trial that shows the combination of toripalimab with GP chemotherapy for RM-NPC patients provides a superior PFS compared to GP alone. Most adverse events were similar between the two arms, but immune-related AEs were more frequent in the toripalimab arm.

NATURE MEDICINE (2021)

添加到收藏夹

Article Chemistry, Medicinal

Conjugation of a Blood Brain Barrier Peptide Shuttle to an Fc Domain for Brain Delivery of Therapeutic Biomolecules

Marco Cavaco et al.

Summary: The incidence of brain diseases is on the rise, necessitating innovative therapeutic strategies. The use of ADCs is limited by the BBB, but linking antibody fragments with BBBpS shows promise in overcoming this barrier. The Fc-PepH3 scaffold has shown potential as a versatile platform for treating various brain conditions.

ACS MEDICINAL CHEMISTRY LETTERS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance

Chisato M. Yamazaki et al.

Summary: In this study, dual-drug ADCs show promising therapeutic potential for treating heterogeneous breast tumors with minimal toxicity and optimal pharmacokinetic profiles. Compared to co-administration of two single-drug variants, the dual-drug ADC exhibits greater treatment effect and survival benefit in xenograft mouse models representing intratumor HER2 heterogeneity and drug resistance.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Review Chemistry, Medicinal

Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety

Massimo Offidani et al.

Summary: Despite challenges with drug resistance, novel therapies like the BCMA-targeted immunotherapy belantamab mafodotin show potential advantages in treating multiple myeloma patients.

DRUG DESIGN DEVELOPMENT AND THERAPY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Denosumab versus romosozumab for postmenopausal osteoporosis treatment

Tomonori Kobayakawa et al.

Summary: Denosumab and romosozumab are effective molecular-targeted drugs for postmenopausal osteoporosis treatment. This study found that romosozumab had a higher potential for improving bone mineral density compared to denosumab in postmenopausal osteoporosis patients.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Hematology

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

David J. Straus et al.

Summary: The updated analysis of the ECHELON-1 study at 5 years showed that A+AVD demonstrated robust improvement in progression-free survival compared to ABVD, with a consistent safety profile. This indicates that A+AVD should be preferred over ABVD for patients with previously untreated stage III or IV classical Hodgkin lymphoma.

LANCET HAEMATOLOGY (2021)

添加到收藏夹

Article Immunology

Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Infection

Rosa Rodriguez-Fernandez et al.

Summary: RSV is a major cause of hospitalizations in infants, and Palivizumab is the only licensed agent for preventing severe RSV infection in high-risk infants. New generation mAbs targeting neutralizing epitopes are expected to provide better protection with fewer injections.

PEDIATRIC INFECTIOUS DISEASE JOURNAL (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Treatment with Ixekizumab Following Secukinumab Failure in Patients with Psoriatic Arthritis: Real-Life Experience from a Resistant Population

Julia Berman et al.

Summary: A retrospective study showed that 83% of PsA patients who switched to Ixekizumab following Secukinumab failure had a primary response, with significant improvements in disease activity indices and skin lesions during treatment.

BIOLOGICS-TARGETS & THERAPY (2021)

添加到收藏夹

Review Medicine, Research & Experimental

An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease

Mario Cazzola et al.

Summary: Various monoclonal antibodies have been tested or are currently under clinical evaluation for the treatment of COPD, divided into those targeting specific pro-inflammatory and pro-neutrophilic cytokines and chemokines, and those acting on T2-mediated inflammation. However, none of these approaches has proven to be effective due to the lack of a dominant cytokine or chemokine in COPD. Advanced understanding of the pathways in COPD may allow for personalized treatments in specific patients.

BIOLOGICS-TARGETS & THERAPY (2021)

添加到收藏夹

Review Dermatology

Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis

Andrea Chiricozzi et al.

Summary: Guselkumab, a fully human monoclonal antibody, has been approved for the treatment of moderate-to-severe plaque psoriasis in adults by selectively inhibiting the p19 subunit of interleukin 23. Clinical trials have shown that it maintains high levels of clinical response over three years, regardless of patient characteristics, with a favorable safety profile.

EUROPEAN JOURNAL OF DERMATOLOGY (2021)

添加到收藏夹

Article Immunology

Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Infection

Rosa Rodriguez-Fernandez et al.

Summary: RSV is the leading cause of hospitalizations in infants globally, and Palivizumab is currently the only approved drug for preventing severe RSV infection in high-risk infants. Advances in monoclonal antibody technology have paved the way for the development of new strategies for preventing RSV infections, with a focus on new neutralizing epitopes and improved half life of antibodies.

PEDIATRIC INFECTIOUS DISEASE JOURNAL (2021)

添加到收藏夹

Article Critical Care Medicine

Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma

Joanne E. Kavanagh et al.

Summary: In patients with severe eosinophilic asthma treated with benralizumab, a significant reduction in asthma exacerbation rates was observed, with a subset of patients achieving super response. Blood eosinophil count increase was associated with treatment nonresponse.

CHEST (2021)

添加到收藏夹

Review Immunology

Transformation of fibroblast-like synoviocytes in rheumatoid arthritis; from a friend to foe

Mohammad Javad Mousavi et al.

Summary: Rheumatoid arthritis (RA) is characterized by swelling and progressive destruction of articular cartilage, with fibroblast-like synoviocytes (FLSs) playing a crucial role in disease progression. FLSs exhibit invasive behavior similar to tumor conditions, leading to recruitment of other immune cells and eventually pannus formation. The cancer-like phenotype of RA FLSs arises from metabolic changes and genetic abnormalities, with implications for targeted treatment strategies.

AUTOIMMUNITY HIGHLIGHTS (2021)

添加到收藏夹

Article Clinical Neurology

Galcanezumab for the prevention of migraine

Lindsay M. Frerichs et al.

Summary: New therapies targeting CGRP for migraine have been widely approved, with galcanezumab being a monoclonal antibody specifically approved for preventive treatment of migraine.

PAIN MANAGEMENT (2021)

添加到收藏夹

Article Endocrinology & Metabolism

A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes

Bart Keymeulen et al.

Summary: The study aimed to evaluate the association between dose-response, safety, tolerability, beta cell function preservation, and immunological effects of otelixizumab in new-onset type 1 diabetes. The results showed that a lower dose of 9 mg of otelixizumab had a metabolic response, while higher doses increased the risk of clinical EBV reactivation. Both adverse events and EBV reactivation were dose dependent and transient, with a potential temporary compromise of immunocompetence.

DIABETOLOGIA (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases

Kate D. Lynch et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)

添加到收藏夹

Article Ophthalmology

HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration

Pravin U. Dugel et al.

OPHTHALMOLOGY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Thera-SAbDab: the Therapeutic Structural Antibody Database

Matthew I. J. Raybould et al.

NUCLEIC ACIDS RESEARCH (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

The blood-brain barrier: Physiology and strategies for drug delivery

Rucha Pandit et al.

ADVANCED DRUG DELIVERY REVIEWS (2020)

添加到收藏夹

Article Oncology

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Laurie H. Sehn et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Allergy

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

Ioana Agache et al.

ALLERGY (2020)

添加到收藏夹

Article Clinical Neurology

Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)

Messoud Ashina et al.

CEPHALALGIA (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Crizanlizumab: First Approval

Hannah A. Blair

DRUGS (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis

Joseph D. Feuerstein et al.

GASTROENTEROLOGY (2020)

添加到收藏夹

Article Oncology

Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial

Michael R. Migden et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Review Medicine, General & Internal

Tumor Microenvironment

Borros Arneth

MEDICINA-LITHUANIA (2020)

添加到收藏夹

Article Clinical Neurology

Emerging therapies for autoimmune myasthenia gravis: Towards treatment without corticosteroids

Martijn R. Tannemaat et al.

NEUROMUSCULAR DISORDERS (2020)

添加到收藏夹

Article Medicine, General & Internal

Teprotumumab for the Treatment of Active Thyroid Eye Disease

R. S. Douglas et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Trial of Anifrolumab in Active Systemic Lupus Erythematosus

Eric F. Morand et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Role of a noncanonical disulfide bond in the stability, affinity, and flexibility of a VHH specific for the Listeria virulence factor InlB

Matthew N. Mendoza et al.

PROTEIN SCIENCE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab

Lionel Rouge et al.

SCIENCE (2020)

添加到收藏夹

Article Medicine, General & Internal

Effects of Interleukin-1β Inhibition on Incident Anemia Exploratory Analyses From a Randomized Trial

Mounica Vallurupalli et al.

ANNALS OF INTERNAL MEDICINE (2020)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Brodalumab in the treatment of chronic plaque psoriasis

Paolo Gisondi et al.

EXPERT OPINION ON BIOLOGICAL THERAPY (2020)

添加到收藏夹

Review Rheumatology

Treatment guidelines in psoriatic arthritis

Alexis Ogdie et al.

RHEUMATOLOGY (2020)

添加到收藏夹

Article Clinical Neurology

Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)

Helmut Butzkueven et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)

添加到收藏夹

Review Clinical Neurology

Safety and Efficacy of Fremanezumab for the Prevention of Migraine: A Meta-Analysis From Randomized Controlled Trials

Bixi Gao et al.

FRONTIERS IN NEUROLOGY (2020)

添加到收藏夹

Review Endocrinology & Metabolism

Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children

Aaron Schindeler et al.

FRONTIERS IN ENDOCRINOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis

F. Locatelli et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Oncology

Rituximab biosimilars in hematologic malignancies: the need for a real-world approach

Pilar Nava-Parada et al.

FUTURE ONCOLOGY (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

When liposomes met antibodies: Drug delivery and beyond

Jiaxing Di et al.

ADVANCED DRUG DELIVERY REVIEWS (2020)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and safety of rituximab for systemic lupus erythematosus treatment: a meta-analysis

Shanshan Wu et al.

AFRICAN HEALTH SCIENCES (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Vedolizumab Therapy in Children With Primary Sclerosing Cholangitis: Data From the Pediatric Primary Sclerosing Cholangitis Consortium

Trevor J. Laborda et al.

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2020)

添加到收藏夹

Article Oncology

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

Gilles Salles et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Endocrinology & Metabolism

Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes

Laura M. Jacobsen et al.

DIABETES TECHNOLOGY & THERAPEUTICS (2020)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Denosumab for cancer-related bone loss

Emanuela Dell'Aquila et al.

EXPERT OPINION ON BIOLOGICAL THERAPY (2020)

添加到收藏夹

Article Clinical Neurology

Long-term safety, tolerability, and efficacy of fremanezumab in migraine A randomized study

Peter J. Goadsby et al.

NEUROLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis

Richard Furie et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Immunology

Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring

Kathy Khoy et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Monoclonal Antibodies and Airway Diseases

Annina Lyly et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Alzheimer's disease: Recent treatment strategies

Miguel Vaz et al.

EUROPEAN JOURNAL OF PHARMACOLOGY (2020)

添加到收藏夹

Review Cell Biology

Development of therapeutic antibodies for the treatment of diseases

Ruei-Min Lu et al.

JOURNAL OF BIOMEDICAL SCIENCE (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

The updated landscape of tumor microenvironment and drug repurposing

Ming-Zhu Jin et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage

Michal Segal-Salto et al.

JHEP REPORTS (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease

Andrew J. Muir et al.

HEPATOLOGY (2019)

添加到收藏夹

Review Microbiology

Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug- Resistant HIV-1 Infection

Mario V. Beccari et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)

添加到收藏夹

Review Chemistry, Medicinal

The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy

Takashi Nakada et al.

CHEMICAL & PHARMACEUTICAL BULLETIN (2019)

添加到收藏夹

Review Oncology

Daratumumab in multiple myeloma

Ajay K. Nooka et al.

CANCER (2019)

添加到收藏夹

Article Endocrinology & Metabolism

Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data

Michael J. Haller et al.

DIABETES (2019)

添加到收藏夹

Review Immunology

Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease

Matthias Friedrich et al.

IMMUNITY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort Study

Benedicte Caron et al.

JOURNAL OF CROHNS & COLITIS (2019)

添加到收藏夹

Review Pediatrics

Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review

Stephen Mac et al.

PEDIATRICS (2019)

添加到收藏夹

Review Medicine, General & Internal

Golimumab for Rheumatoid Arthritis

Eleftherios Pelechas et al.

JOURNAL OF CLINICAL MEDICINE (2019)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Bispecific antibodies: a mechanistic review of the pipeline

Aran F. Labrijn et al.

NATURE REVIEWS DRUG DISCOVERY (2019)

添加到收藏夹

Article Medicine, General & Internal

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

Kevan C. Herold et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Review Multidisciplinary Sciences

Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis

Benjamin Castagne et al.

PLOS ONE (2019)

添加到收藏夹

Article Multidisciplinary Sciences

A proof of concept for structure-based vaccine design targeting RSV in humans

Michelle C. Crank et al.

SCIENCE (2019)

添加到收藏夹

Review Immunology

Biology of Infection and Disease Pathogenesis to Guide RSV Vaccine Development

Seyhan Boyoglu-Barnum et al.

FRONTIERS IN IMMUNOLOGY (2019)

添加到收藏夹

Review Oncology

Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma

Bertil E. Damato et al.

CANCERS (2019)

添加到收藏夹

Review Immunology

Human monoclonal antibodies for discovery, therapy, and vaccine acceleration

Emanuele Andreano et al.

CURRENT OPINION IN IMMUNOLOGY (2019)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Rituximab biosimilars for lymphoma in Europe

Wojciech Jurczak et al.

EXPERT OPINION ON BIOLOGICAL THERAPY (2019)

添加到收藏夹

Article Medicine, General & Internal

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

Bruce A. C. Cree et al.

LANCET (2019)

添加到收藏夹

Article Oncology

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

Udai Banerji et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Oncology

An Overview of Monoclonal Antibodies

Virginia Bayer

SEMINARS IN ONCOLOGY NURSING (2019)

添加到收藏夹

Article Medicine, General & Internal

Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder

Takashi Yamamura et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti-CD3ε mAb in new-onset type 1 diabetes mellitus patients

Georgios Vlasakakis et al.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)

添加到收藏夹

Article Endocrinology & Metabolism

Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7years from diagnosis

Ana Luisa Perdigoto et al.

DIABETOLOGIA (2019)

添加到收藏夹

Article Oncology

Necitumumab for the treatment of advanced non-small-cell lung cancer

Asuncion Diaz-Serrano et al.

FUTURE ONCOLOGY (2019)

添加到收藏夹

Review Rheumatology

IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review

Atsushi Ogata et al.

MODERN RHEUMATOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

G. von Minckwitz et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Medicine, General & Internal

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura

M. Scully et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Review Hematology

Brentuximab vedotin in T-cell lymphoma

Carrie Van der Weyden et al.

EXPERT REVIEW OF HEMATOLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

ACG Clinical Guideline: Ulcerative Colitis in Adults

David T. Rubin et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2019)

添加到收藏夹

Article Hematology

Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval

Adam Yuh Lin et al.

BLOOD ADVANCES (2019)

添加到收藏夹

Review Hematology

Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria

Robert M. Stern et al.

THERAPEUTIC ADVANCES IN HEMATOLOGY (2019)

添加到收藏夹

Review Oncology

Chimeric antigen receptor T-cell therapies for lymphoma

Jennifer N. Brudno et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

添加到收藏夹

Review Rheumatology

Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis

P. Kawalec et al.

RHEUMATOLOGY INTERNATIONAL (2018)

添加到收藏夹

Article Medicine, Research & Experimental

Cell Biology and Pathophysiology of α-Synuclein

Jacqueline Burre et al.

COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)

添加到收藏夹

Article Clinical Neurology

ARISE: A Phase 3 randomized trial of erenumab for episodic migraine

David W. Dodick et al.

CEPHALALGIA (2018)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Inflammatory and Cholesterol Risk in the FOURIER Trial

Erin A. Bohula et al.

CIRCULATION (2018)

添加到收藏夹

Review Pharmacology & Pharmacy

Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease

Amy Hemperly et al.

CLINICAL PHARMACOKINETICS (2018)

添加到收藏夹

Article Endocrinology & Metabolism

Low-Dose Anti-Thymocyte Globulin (ATG) Preserves -Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes

Michael J. Haller et al.

DIABETES CARE (2018)

添加到收藏夹

Review Pharmacology & Pharmacy

Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis

Yvette N. Lamb et al.

DRUGS (2018)

添加到收藏夹

Article Oncology

Durvalumab in urothelial cancers

Pernelle Lavaud et al.

EXPERT REVIEW OF ANTICANCER THERAPY (2018)

添加到收藏夹

Article Oncology

Atezolizumab in urothelial bladder carcinoma

Zineb Hamilou et al.

FUTURE ONCOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis

Stephen A. Harrison et al.

GASTROENTEROLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases

Julien Kirchgesner et al.

GASTROENTEROLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Is the Pharmacokinetic Profile of a First Anti-TNF Predictive of the Clinical Outcome and Pharmacokinetics of a Second Anti-TNF?

Xavier Roblin et al.

INFLAMMATORY BOWEL DISEASES (2018)

添加到收藏夹

Review Oncology

Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma

Veerendra Koppolu et al.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2018)

添加到收藏夹

Editorial Material Medicine, General & Internal

End of the road for daclizumab in multiple sclerosis

[Anonymous]

LANCET (2018)

添加到收藏夹

Article Medicine, General & Internal

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

Jae H. Park et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Review Pharmacology & Pharmacy

Therapeutic antibodies: A new era in the treatment of respiratory diseases?

T. Secher et al.

PHARMACOLOGY & THERAPEUTICS (2018)

添加到收藏夹

Review Multidisciplinary Sciences

CAR T cell immunotherapy for human cancer

Carl H. June et al.

SCIENCE (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Fei Tang et al.

CELL AND BIOSCIENCE (2018)

添加到收藏夹

Article Pharmacology & Pharmacy

Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia

Jeffrey Baron et al.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study

Ronald F. van Vollenhoven et al.

LANCET (2018)

添加到收藏夹

Article Oncology

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Article Dermatology

Ustekinumab for the treatment of psoriasis: an evidence update

Zenas Z. N. Yiu et al.

SEMINARS IN CUTANEOUS MEDICINE AND SURGERY (2018)

添加到收藏夹

Review Oncology

Inotuzumab Ozogamicin: A Review in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia

Zaina T. Al-Salama

TARGETED ONCOLOGY (2018)

添加到收藏夹

Review Pharmacology & Pharmacy

Emerging therapeutic strategies for minimal change disease and focal and segmental glomerulosclerosis

Rossella Siligato et al.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)

添加到收藏夹

Article Medicine, General & Internal

Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks A Randomized Clinical Trial

Aleena Banerji et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)

添加到收藏夹

Article Clinical Neurology

Galcanezumab in chronic migraine The randomized, double-blind, placebo-controlled REGAIN study

Holland C. Detke et al.

NEUROLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

G. G. Schwartz et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Review Medicine, General & Internal

Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma

Florence Roufosse

FRONTIERS IN MEDICINE (2018)

添加到收藏夹

Review Respiratory System

Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness

Corrado Pelaia et al.

THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2018)

添加到收藏夹

Review Gastroenterology & Hepatology

Immunogenicity of biologics in inflammatory bowel disease

Severine Vermeire et al.

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2018)

添加到收藏夹

Review Medicine, General & Internal

Sickle Cell Disease: Advances in Treatment

Renee V. Gardner

OCHSNER JOURNAL (2018)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Golimumab for the treatment of ulcerative colitis

Mathurin Flamant et al.

EXPERT OPINION ON BIOLOGICAL THERAPY (2017)

添加到收藏夹

Article Oncology

Olaratumab for the treatment of soft-tissue sarcoma

Alexandra Pender et al.

FUTURE ONCOLOGY (2017)

添加到收藏夹

Review Biochemistry & Molecular Biology

Natalizumab in Multiple Sclerosis: Long-Term Management

Marinella Clerico et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)

添加到收藏夹

Article Medicine, General & Internal

Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease

Magali Lemaitre et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)

添加到收藏夹

Article Medicine, General & Internal

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

Kristian Reich et al.

LANCET (2017)

添加到收藏夹

Article Clinical Neurology

Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies

Pei-Ran Ho et al.

LANCET NEUROLOGY (2017)

添加到收藏夹

Article Clinical Neurology

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

Stewart Tepper et al.

LANCET NEUROLOGY (2017)

添加到收藏夹

Article Multidisciplinary Sciences

A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy

Marta Luksza et al.

NATURE (2017)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Strategies and challenges for the next generation of antibody drug conjugates

Alain Beck et al.

NATURE REVIEWS DRUG DISCOVERY (2017)

添加到收藏夹

Article Clinical Neurology

Erenumab (AMG 334) in episodic migraine Interim analysis of an ongoing open-label study

Messoud Ashina et al.

NEUROLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

Marc S. Sabatine et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Medicine, General & Internal

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection

M. H. Wilcox et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Medicine, General & Internal

Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease

K. I. Ataga et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Medicine, General & Internal

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

Johannes Oldenburg et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Medicine, General & Internal

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

Kim A. Papp et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Medicine, General & Internal

Idarucizumab for Dabigatran Reversal - Full Cohort Analysis

Charles V. Pollack et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Medicine, General & Internal

Fremanezumab for the Preventive Treatment of Chronic Migraine

Stephen D. Silberstein et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Medicine, General & Internal

A Controlled Trial of Erenumab for Episodic Migraine

Peter J. Goadsby et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Medicine, General & Internal

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

Hagop Kantarjian et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Medicine, General & Internal

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

P. M. Ridker et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Review Medicine, General & Internal

Treatment adherence in hemophilia

Courtney D. Thornburg et al.

PATIENT PREFERENCE AND ADHERENCE (2017)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Tocilizumab (Actemra)

Martin Sheppard et al.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)

添加到收藏夹

Article Rheumatology

Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors

Roy Fleischmann et al.

ARTHRITIS & RHEUMATOLOGY (2017)

添加到收藏夹

Review Immunology

Single-Domain Antibodies As versatile Affinity Reagents for Analytical and Diagnostic Applications

Gualberto Gonzalez-Sapienza et al.

FRONTIERS IN IMMUNOLOGY (2017)

添加到收藏夹

Review Medicine, Research & Experimental

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience

Gilles Salles et al.

ADVANCES IN THERAPY (2017)

添加到收藏夹

Review Pharmacology & Pharmacy

Reslizumab in Eosinophilic Asthma: A Review

Emma D. Deeks et al.

DRUGS (2017)

添加到收藏夹

Article Immunology

Mobilization without immune depletion fails to restore immunological tolerance or preserve beta cell function in recent onset type 1 diabetes

M. J. Haller et al.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2016)

添加到收藏夹

Review Urology & Nephrology

Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children

Pietro Ravani et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)

添加到收藏夹

Article Immunology

Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes

James E. Tooley et al.

EUROPEAN JOURNAL OF IMMUNOLOGY (2016)

添加到收藏夹

Article Gastroenterology & Hepatology

Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial

Filip Baert et al.

GUT (2016)

添加到收藏夹

Article Oncology

90 Y-ibritumomab tiuxetan: a nearly forgotten opportunity

Patrizia Mondello et al.

ONCOTARGET (2016)

添加到收藏夹

Review Immunology

Distinct antibody species: structural differences creating therapeutic opportunities

Serge Muyldermans et al.

CURRENT OPINION IN IMMUNOLOGY (2016)

添加到收藏夹

Article Endocrinology & Metabolism

Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes

Michael J. Haller et al.

DIABETES (2016)

添加到收藏夹

Article Endocrinology & Metabolism

Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial

Stephen E. Gitelman et al.

DIABETOLOGIA (2016)

添加到收藏夹

Article Pharmacology & Pharmacy

Obiltoxaximab: First Global Approval

Sarah L. Greig

DRUGS (2016)

添加到收藏夹

Review Pharmacology & Pharmacy

Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations

G. Reda et al.

EXPERT OPINION ON DRUG SAFETY (2016)

添加到收藏夹

Article Neurosciences

Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice

Ksenia V. Kastanenka et al.

JOURNAL OF NEUROSCIENCE (2016)

添加到收藏夹

Article Oncology

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

Howard L. Kaufman et al.

LANCET ONCOLOGY (2016)

添加到收藏夹

Article Multidisciplinary Sciences

The antibody aducanumab reduces Aβ plaques in Alzheimer's disease

Jeff Sevigny et al.

NATURE (2016)

添加到收藏夹

Article Medicine, General & Internal

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

K. B. Gordon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Medicine, General & Internal

Adalimumab in Patients with Active Noninfectious Uveitis

Glenn J. Jaffe et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Medicine, General & Internal

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

F. Cosman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

R. L. Ferris et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Medicine, General & Internal

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

Alexa B. Kimball et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Review Oncology

Dinutuximab: A Review in High-Risk Neuroblastoma

Sheridan M. Hoy

TARGETED ONCOLOGY (2016)

添加到收藏夹

Article Immunology

Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes

S. Alice Long et al.

SCIENCE IMMUNOLOGY (2016)

添加到收藏夹

Review Gastroenterology & Hepatology

Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed

J. P. Gisbert et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)

添加到收藏夹

Review Oncology

Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis

Sarah S. Thomas et al.

BIODRUGS (2015)

添加到收藏夹

Editorial Material Cardiac & Cardiovascular Systems

Statin Intolerance

David H. Fitchett et al.

CIRCULATION (2015)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Monoclonal antibodies for renal diseases: current concepts and ongoing treatments

Domenico Santoro et al.

EXPERT OPINION ON BIOLOGICAL THERAPY (2015)

添加到收藏夹

Article Gastroenterology & Hepatology

Immunopathogenesis of IBD: current state of the art

Heitor S. P. de Souza et al.

Nature Reviews Gastroenterology & Hepatology (2015)

添加到收藏夹

Review Oncology

Renal Toxicities of Targeted Therapies

Anum Abbas et al.

TARGETED ONCOLOGY (2015)

添加到收藏夹

Article Behavioral Sciences

An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis

Neeta Garg et al.

BRAIN AND BEHAVIOR (2015)

添加到收藏夹

Article Medicine, Research & Experimental

Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes

Michael J. Haller et al.

JOURNAL OF CLINICAL INVESTIGATION (2015)

添加到收藏夹

Article Gastroenterology & Hepatology

Ramucirumab for gastric cancer

Kohei Shitara et al.

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2015)

添加到收藏夹

Review Gastroenterology & Hepatology

Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease

R. W. Stidham et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)

添加到收藏夹

Review Medicine, General & Internal

Biological Agents for Moderately to Severely Active Ulcerative Colitis A Systematic Review and Network Meta-analysis

Silvio Danese et al.

ANNALS OF INTERNAL MEDICINE (2014)

添加到收藏夹

Review Immunology

Innate and adaptive immunity in inflammatory bowel disease

Alessandra Geremia et al.

AUTOIMMUNITY REVIEWS (2014)

添加到收藏夹

Review Immunology

Monoclonal antibodies in treatment of multiple sclerosis

P. S. Rommer et al.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2014)

添加到收藏夹

Article Gastroenterology & Hepatology

Comparative Effectiveness of Infliximab and Adalimumab for Crohn's Disease

Mark T. Osterman et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)

添加到收藏夹

Article Endocrinology & Metabolism

B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year Results

Mark D. Pescovitz et al.

DIABETES CARE (2014)

添加到收藏夹

Article Infectious Diseases

Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia

Y. -A. Que et al.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2014)

添加到收藏夹

Article Oncology

Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia

John L. Reagan et al.

FUTURE ONCOLOGY (2014)

添加到收藏夹

Article Gastroenterology & Hepatology

Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

William J. Sandborn et al.

GASTROENTEROLOGY (2014)

添加到收藏夹

Article Gastroenterology & Hepatology

Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis

Remo Panaccione et al.

GASTROENTEROLOGY (2014)

添加到收藏夹

Article Clinical Neurology

Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab

Reuben Mari Valenzuela et al.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2014)

添加到收藏夹

Review Biochemistry & Molecular Biology

Complement activation-related pseudoallergy: A stress reaction in blood triggered by nanomedicines and biologicals

Janos Szebeni

MOLECULAR IMMUNOLOGY (2014)

添加到收藏夹

Review Urology & Nephrology

Rituximab in Systemic Lupus Erythematosus and Lupus Nephritis

Hannah Beckwith et al.

NEPHRON CLINICAL PRACTICE (2014)

添加到收藏夹

Article Medicine, General & Internal

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

Stephen Salloway et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

添加到收藏夹

Article Medicine, General & Internal

Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis

Lisa A. Beck et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

添加到收藏夹

Article Medicine, General & Internal

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

Hector G. Ortega et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

添加到收藏夹

Article Medicine, General & Internal

Hydroxychloroquine: A multifaceted treatment in lupus

Nathalie Costedoat-Chalumeau et al.

PRESSE MEDICALE (2014)

添加到收藏夹

Review Infectious Diseases

Raxibacumab: potential role in the treatment of inhalational anthrax

Carlos E. Kummerfeldt

INFECTION AND DRUG RESISTANCE (2014)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

New Therapies Targeting apoB Metabolism for High-Risk Patients with Inherited Dyslipidaemias: What Can the Clinician Expect?

Amirhossein Sahebkar et al.

CARDIOVASCULAR DRUGS AND THERAPY (2013)

添加到收藏夹

Article Rheumatology

Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice

Joerg Kaufmann et al.

CLINICAL RHEUMATOLOGY (2013)

添加到收藏夹

Article Endocrinology & Metabolism

Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders

Kevan C. Herold et al.

DIABETES (2013)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Rituximab in the treatment of non-Hodgkin's lymphoma - a critical evaluation of randomized controlled trials

Morag Meriel Griffin et al.

EXPERT OPINION ON BIOLOGICAL THERAPY (2013)

添加到收藏夹

Article Biochemistry & Molecular Biology

Structural Basis for Treating Tumor Necrosis Factor α (TNFα)-associated Diseases with the Therapeutic Antibody Infliximab

Shuaiyi Liang et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2013)

添加到收藏夹

Article Gastroenterology & Hepatology

Addition of thiopurines can recapture response in patients with Crohn's disease who have lost response to anti-tumor necrosis factor monotherapy

David E. H. Ong et al.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2013)

添加到收藏夹

Article Medicine, General & Internal

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

Cem Gabay et al.

LANCET (2013)

添加到收藏夹

Article Medicine, General & Internal

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

William J. Sandborn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

添加到收藏夹

Article Endocrinology & Metabolism

Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial

Stephen E. Gitelman et al.

LANCET DIABETES & ENDOCRINOLOGY (2013)

添加到收藏夹

Article Gastroenterology & Hepatology

A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease

Gary R. Lichtenstein et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)

添加到收藏夹

Article Pharmacology & Pharmacy

Catumaxomab In Malignant Ascites

James E. Frampton

DRUGS (2012)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Ranibizumab for age-related macular degeneration

Dilsher S. Dhoot et al.

EXPERT OPINION ON BIOLOGICAL THERAPY (2012)

添加到收藏夹

Article Immunology

Rituximab: emerging treatment strategies of immune-mediated glomerular disease

Andrea G. Kattah et al.

EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2012)

添加到收藏夹

Article Gastroenterology & Hepatology

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

William J. Sandborn et al.

GASTROENTEROLOGY (2012)

添加到收藏夹

Article Medicine, General & Internal

Denosumab: mechanism of action and clinical outcomes

D. A. Hanley et al.

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2012)

添加到收藏夹

Article Biochemistry & Molecular Biology

Structural Basis of C-terminal β-Amyloid Peptide Binding by the Antibody Ponezumab for the Treatment of Alzheimer's Disease

Sherry L. La Porte et al.

JOURNAL OF MOLECULAR BIOLOGY (2012)

添加到收藏夹

Article Clinical Neurology

Treatment effect of natalizumab on relapse outcomes in multiple sclerosis patients despite ongoing MRI activity

David Bates et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2012)

添加到收藏夹

Article Medicine, General & Internal

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Alasdair J. Coles et al.

LANCET (2012)

添加到收藏夹

Article Medicine, General & Internal

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Sunil Verma et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

Article Pharmacology & Pharmacy

Ipilimumab: A Novel Treatment for Metastatic Melanoma

Morgan E. Culver et al.

ANNALS OF PHARMACOTHERAPY (2011)

添加到收藏夹

Article Hematology

Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease

Diana R. Gutsaeva et al.

BLOOD (2011)

添加到收藏夹

Article Clinical Neurology

Anti-β-Amyloid Immunotherapy for Alzheimer's Disease: Focus on Bapineuzumab

Francesco Panza et al.

CURRENT ALZHEIMER RESEARCH (2011)

添加到收藏夹

Article Gastroenterology & Hepatology

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

Walter Reinisch et al.

GUT (2011)

添加到收藏夹

Article Medicine, General & Internal

Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial

Nicole Sherry et al.

LANCET (2011)

添加到收藏夹

Review Medicine, General & Internal

MECHANISMS OF DISEASE The Pathogenesis of Rheumatoid Arthritis

Iain B. McInnes et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

添加到收藏夹

Review Physiology

Type 1 Diabetes: Etiology, Immunology, and Therapeutic Strategies

Tom L. Van Belle et al.

PHYSIOLOGICAL REVIEWS (2011)

添加到收藏夹

Article Cell Biology

Human CD3 Transgenic Mice: Preclinical Testing of Antibodies Promoting Immune Tolerance

Chantal Kuhn et al.

SCIENCE TRANSLATIONAL MEDICINE (2011)

添加到收藏夹

Article Clinical Neurology

Natalizumab (Tysabri)

D. T. Selewski et al.

AMERICAN JOURNAL OF NEURORADIOLOGY (2010)

添加到收藏夹

Review Oncology

Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review

S. Welch et al.

ANNALS OF ONCOLOGY (2010)

添加到收藏夹

Article Oncology

131-Iodine Tositumomab in lymphoma

A.E. Haynes et al.

Current Oncology (2010)

添加到收藏夹

Review Medicine, Research & Experimental

Certolizumab pegol

Niti Goel et al.

MABS (2010)

添加到收藏夹

Review Medicine, Research & Experimental

Canakinumab

Eugen Dhimolea

MABS (2010)

添加到收藏夹

Article Medicine, General & Internal

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.

Jean Frederic Colombel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

添加到收藏夹

Article Rheumatology

The effectiveness of anti-TNF-α therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis

Suzanne Lloyd et al.

RHEUMATOLOGY (2010)

添加到收藏夹

Review Immunology

Monoclonal antibody-induced cytokine-release syndrome

Peter J. Bugelski et al.

EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2009)

添加到收藏夹

Article Gastroenterology & Hepatology

Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study

H. Fidder et al.

GUT (2009)

添加到收藏夹

Article Gastroenterology & Hepatology

Open-Label Study of Adalimumab in Patients with Ulcerative Colitis Including Those with Prior Loss of Response or Intolerance to Infliximab

Waqqas Afif et al.

INFLAMMATORY BOWEL DISEASES (2009)

添加到收藏夹

Article Medicine, General & Internal

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

Mark D. Pescovitz et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

添加到收藏夹

Article Dermatology

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Alan Menter et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)

添加到收藏夹

Article Orthopedics

Epidemiology of Diabetes and Diabetes-Related Complications

Anjali D. Deshpande et al.

PHYSICAL THERAPY (2008)

添加到收藏夹

Article Hematology

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria

Robert A. Brodsky et al.

BLOOD (2008)

添加到收藏夹

Article Gastroenterology & Hepatology

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial

W. J. Sandborn et al.

GUT (2007)

添加到收藏夹

Article Medicine, General & Internal

Maintenance therapy with certolizumab pegol for Crohn's disease

Stefan Schreiber et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

添加到收藏夹

Article Multidisciplinary Sciences

Adaptive TGF-β-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment

Sylvaine You et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)

添加到收藏夹

Article Oncology

Certolizumab pegol in Crohn's disease

Stephanie K. A. Blick et al.

BIODRUGS (2007)

添加到收藏夹

Article Gastroenterology & Hepatology

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial

Jean-Frederic Colombel et al.

GASTROENTEROLOGY (2007)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Adalimumab for rheumatoid arthritis

Paraskevi V. Voulgari et al.

EXPERT OPINION ON BIOLOGICAL THERAPY (2006)

添加到收藏夹

Review Gastroenterology & Hepatology

Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules

Kazuhiko Nakamura et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2006)

添加到收藏夹

Article Dermatology

Efalizumab in the treatment of psoriasis

Aditya K. Gupta et al.

JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2006)

添加到收藏夹

Article Gastroenterology & Hepatology

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

SB Hanauer et al.

GASTROENTEROLOGY (2006)

添加到收藏夹

Review Pharmacology & Pharmacy

Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity

J Szebeni

TOXICOLOGY (2005)

添加到收藏夹

Article Medicine, General & Internal

Infliximab for induction and maintenance therapy for ulcerative colitis

P Rutgeerts et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

添加到收藏夹

Article Biochemistry & Molecular Biology

Structure of a shark IgNAR antibody variable domain and modeling of an early-developmental isotype

VA Streltsov et al.

PROTEIN SCIENCE (2005)

添加到收藏夹

Article Medicine, General & Internal

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

B Keymeulen et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

添加到收藏夹

Article Biochemical Research Methods

Design of humanized antibodies: From anti-Tac to Zenapax

N Tsurushita et al.

METHODS (2005)

添加到收藏夹

Article Oncology

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

M Moroni et al.

LANCET ONCOLOGY (2005)

添加到收藏夹

Review Oncology

Overview of monoclonal antibodies in cancer therapy: present and promise

M Stern et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2005)

添加到收藏夹

Review Medicine, General & Internal

Coronary stenting and abciximab in primary angioplasty for ST-segment-elevation myocardial infarction

G De Luca et al.

QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2005)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Human antibodies from transgenic animals

N Lonberg

NATURE BIOTECHNOLOGY (2005)

添加到收藏夹

Article Rheumatology

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy - A randomized, placebo-controlled, 52-week trial

EC Keystone et al.

ARTHRITIS AND RHEUMATISM (2004)

添加到收藏夹

Article Immunology

Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis

B Eksteen et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2004)

添加到收藏夹

Article Biochemistry & Molecular Biology

Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures

M Zemlin et al.

JOURNAL OF MOLECULAR BIOLOGY (2003)

添加到收藏夹

Article Medicine, General & Internal

Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease

F Baert et al.

NEW ENGLAND JOURNAL OF MEDICINE (2003)

添加到收藏夹

Review Biochemistry & Molecular Biology

Engineered antibodies

Peter J. Hudson et al.

NATURE MEDICINE (2003)

添加到收藏夹

Article Oncology

A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours

RJ Francis et al.

BRITISH JOURNAL OF CANCER (2002)

添加到收藏夹

Article Medicine, General & Internal

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

SB Hanauer et al.

LANCET (2002)

添加到收藏夹

Review Oncology

Improving the efficacy of antibody-based cancer therapies

P Carter

NATURE REVIEWS CANCER (2001)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Recombinant antibodies for cancer diagnosis and therapy

C Souriau et al.

EXPERT OPINION ON BIOLOGICAL THERAPY (2001)

添加到收藏夹

Article Gastroenterology & Hepatology

MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease)

AJ Grant et al.

HEPATOLOGY (2001)

添加到收藏夹

Therapeutic Antibodies in Medicine

相关参考文献